BioCardia, Inc. Deferred Revenue
BioCardia, Inc. (BCDA) had Deferred Revenue of $60.00 thousand as of 2018-03-31, per its 10-Q filed 2018-05-10.
Discontinued › Balance Sheet › Liabilities › Liabilities, Current › Deferred Revenue, Current
us-gaap:DeferredRevenueCurrent · last filed 2019-04-02
- 2018-03-31: Deferred Revenue, Current $60.00K.
- 2017-12-31: Deferred Revenue, Current $167.00K.
- 2017-09-30: Deferred Revenue, Current $160.00K.
- 2017-06-30: Deferred Revenue, Current $153.00K.
| Period end | Deferred Revenue, Current |
|---|---|
| 2018-03-31 | $60.00K 10-Q · filed 2018-05-10 |
| 2017-12-31 | $167.00K 10-K · filed 2019-04-02 |
| 2017-09-30 | $160.00K 10-Q · filed 2017-11-09 |
| 2017-06-30 | $153.00K 10-Q · filed 2017-08-14 |
| 2017-03-31 | $72.00K 10-Q · filed 2017-05-11 |
| 2016-12-31 | $71.00K 10-K · filed 2018-03-16 |
| 2015-12-31 | $39.00K 10-K · filed 2017-03-30 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| DYADIC INTERNATIONAL INC (DYAI) | United States | $0.016B | |
| Passage BIO, Inc. (PASG) | United States | $0.015B | -0.43 |
| Pluri Inc. (PLUR) | $0.014B | ||
| INTENSITY THERAPEUTICS, INC. (INTS) | United States | $0.013B | -1.08 |
| BRAINSTORM CELL THERAPEUTICS INC. (BCLI) | United States | $0.013B | -1.05 |
| Jasper Therapeutics, Inc. (JSPR) | United States | $0.020B | -0.37 |
| Estrella Immunopharma, Inc. (ESLA) | United States | $0.020B | |
| IN8BIO, INC. (INAB) | United States | $0.012B | -0.76 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |